The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC.

ABSTRACT: Brain metastases are more and more common among patients with non-small cell lung cancer (NSCLC). TKI therapy could provide ideal outcomes for patients harboring epidermal growth factor receptor or ALK mutations. For wild-type patients, however, survival is poor because there are few effective treatments other than radiotherapy. Immune checkpoint inhibitors (ICIs) have changed the management of advanced NSCLC. However, the exclusion of patients with active brain metastasis (BM) from most ICI trials precludes the generalization of results. Accordingly, a variety of appropriate real-world studies and clinical trials are being developed to evaluate tumor response. Increasingly encouraging results have suggested that ICIs could be active in the central nervous system (CNS) in select patients w

SUBMITTER: Li J 

PROVIDER: S-EPMC9152109 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature